Multi-Strain Probiotic Composition for Chemotherapy-Induced Diarrhea
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chemotherapy-induced diarrhea (CID) lack effective and safe probiotic interventions, as existing drugs have single mechanisms of action and significant side effects, disrupting the intestinal flora and causing further disorders.
Innovation Solution
A probiotic composition comprising Bifidobacterium bifidum, Enterococcus avium, Lactobacillus salivarius, Limosilactobacillus fermentum, and Parabacteroides distasonis strains, or their pure cultures, formulated with lyoprotectants and carriers, to inhibit pathogenic bacteria, repair intestinal barriers, and alleviate diarrhea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional drugs are used to treat chemotherapy-induced diarrhea, then diarrhea symptoms can be controlled, but the intestinal flora is disrupted and harmful factors increase
Solution Approach 1:
The patent applies this principle by using probiotics to convert the harmful effect of chemotherapy-induced flora disruption into a beneficial state. The probiotic strains (Bifidobacterium, Lactobacillus, Parabacteroides, etc.) restore beneficial intestinal flora, produce short-chain fatty acids, and inhibit pathogenic bacteria, thereby transforming the harmful chemotherapy side effect into a therapeutic opportunity for flora rebalancing.
Solution Approach 2:
The patent uses probiotic strains as intermediary substances that mediate between the harmful chemotherapy drugs and the intestinal flora. These probiotics act as protective intermediaries that prevent direct harmful effects, produce protective metabolites, and restore the intestinal microecology without interfering with the chemotherapy treatment itself.
2Reliability
If existing probiotic treatments are used, then intestinal health can be maintained, but the treatment mechanism is single and effectiveness is limited
Solution Approach 1:
The patent merges multiple probiotic strains (Bifidobacterium bifidum, Lactobacillus salivarius, Parabacteroides distasonis, Limosilactobacillus fermentum, Enterococcus avium) into a composite formulation. This combination creates synergistic effects where different strains perform complementary functions: some produce short-chain fatty acids, others inhibit specific pathogenic bacteria, and others strengthen the intestinal barrier, thereby achieving more comprehensive and adaptable treatment than single-strain probiotics.
Solution Approach 2:
The multi-strain probiotic formulation exhibits multi-functionality by simultaneously performing multiple tasks: restoring diverse intestinal flora, producing various beneficial metabolites (short-chain fatty acids, vitamins), inhibiting multiple types of pathogenic bacteria, and strengthening the intestinal barrier. This universal approach allows the probiotic to address multiple aspects of intestinal health and adapt to different patient needs.
Data Source
AI summary
Provided in the present invention is a probiotic. The probiotic includes Parabacteroides distasonis with the microbial deposit number of CCTCC NO: M20222033, Limosilactobacillus fermentum with the microbial deposit number of CCTCC NO: M2023352, Lactobacillus salivarius with the microbial deposit number of CCTCC NO: M2023348, Enterococcus avium with the microbial deposit number of CCTCC NO: M2023350, and Bifidobacterium bifidum with the microbial deposit number of CCTCC NO: M2023349. The probiotic has good safety, has antioxidant activity, can inhibit pathogenic bacteria, can alleviate colon injury, can inhibit inflammation, and can alleviate diarrhea caused by chemotherapeutic drugs.